<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1779">
  <stage>Registered</stage>
  <submitdate>14/12/2007</submitdate>
  <approvaldate>14/12/2007</approvaldate>
  <nctid>NCT00574743</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients</studytitle>
    <scientifictitle>A 12-month, Single-blind, Randomized, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of ERL080A Compared With MMF in de Novo Heart Recipients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CERL080A2401</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Transplantation</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Enteric-coated Mycophenolate Sodium

No Intervention: 2 - 

Active Comparator: 1 - 


Treatment: drugs: Enteric-coated Mycophenolate Sodium


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>Inclusion criteria

          -  Male or female cardiac patients 18-65 years old undergoing primary heart
             transplantation treated with CS-ME and corticosteroids as basic immunosuppression.

          -  Females of childbearing potential must have a negative serum pregnancy test within 7
             days prior to enrollment. Effective contraception must be used during the trial and
             for 6 weeks following discontinuation of the study medication, even where there has
             been a history of infertility.

          -  Patients who are willing and able to participate in the full course of the study and
             from whom written informed consent has been obtained.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer />
    <exclusivecriteria>Exclusion criteria

          -  Patients with donor hearts greater than 60 years of age and/or with cold ischemia time
             of more than 6 hours and/or donor hearts which have obvious coronary disease or are
             known to have heart disease at time of transplant.

          -  Patients on Left Ventricular Assist Device who have received any immunotherapy prior
             to transplantation or who are scheduled to receive immunotherapy thereafter.

          -  Patients with Panel Reactive Antibodies (PRA) 25%.

          -  Patients with serum creatinine 3.0mg/dL..

          -  Females of childbearing potential who are planning to become pregnant, who are
             pregnant and/or lactating, who are unwilling to use effective means of contraception.

          -  Patients with a history of significant coagulopathy or medical condition requiring
             long term anti-coagulation after transplantation (low aspirin treatment is allowed).

        Other protocol-defined inclusion/exclusion criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>162</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Novartis Investigative site, Sydney, Australia - Sydney</hospital>
    <postcode> - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Cordoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ottawa</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the safety and efficacy of EC-MPS (ERL080) in comparison to MMF in
      de novo heart recipients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00574743</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis</name>
      <address>Novartis</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>